Home » Newsletters » BioWorld Science

BioWorld Science

June 23, 2009

View Archived Issues

Esomeprazole improves GERD in infants

New data on rifaximin in hepatic encephalopathy, C. difficile infection

AstraZeneca presents P2X7 receptor antagonists for the treatment of rheumatoid arthritis

Nanoparticle-based micelles specifically target diseased vasculature in atherosclerotic mice

Companies collaborate on LTX-315/GV-1001 combination for cancer

Isotechnika enters strategic partnership with Paladin Labs for voclosporin

Arrow Therapeutics discloses Aurora kinase inhibitors for cancer treatment

Novel beta-lactamase inhibitors in development at Protez for the treatment of bacterial infections

INT-131 improves insulin sensitivity and glucose metabolism in phase IIa type 2 diabetes trial

Cell Therapeutics announces results from clinical studies of pixantrone in NHL

PharmaMar initiates treatment in phase I clinical trial of antitumor compound PM-1183

GlaxoSmithKline launches Allermist for allergic rhinitis in Japan

Pfizer discovers glucocorticoid receptor agonists for the treatment of asthma

Amicus Therapeutics seeks FDA approval for phase III Amigal trial for Fabry disease

Clinical data show activity of once-weekly LY-2189265

Mayo Clinic reports results of prostate cancer study with ipilimumab

Snapshots: Recent studies of liraglutide in type 2 diabetes

Merck & Co. and Schering-Plough receive FTC request for additional information for merger

Neovacs to further test TNF-alpha kinoid candidate following phase I/II results

NeurogesX and Astellas enter commercialization agreement for Qutenza

Encouraging phase I/II data for ARQ-197 in solid tumors

GlaxoSmithKline launches Tykerb for HER2-positive breast cancer in Japan

First clinical study of ITCA-650 shows sustained glucose lowering in type 2 diabetes

Oncothyreon and Merck KGaA initiate phase III Stimuvax trial in breast cancer

Diamyd commences treatment in study of Diamyd diabetes vaccine in children

Vical receives milestone payment from Merck & Co. for pDNA cancer vaccine